New vaccine aims to shield kids from Post-Transplant virus

NCT ID NCT03354728

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a vaccine called CMV-MVA Triplex in 80 children who have had a stem cell transplant and are at risk for CMV infection. The goal is to find the best dose and see if it safely prevents CMV reactivation. Participants receive the vaccine and are monitored for side effects and effectiveness over one year.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

CMV-MVA Triplex Vaccine

What this could lead to

If it works, this vaccine could help prevent serious CMV infections in children after stem cell transplants, reducing complications and the need for antiviral drugs.

What could go wrong

This is an early phase 1/2 trial with only 80 participants, so results may not apply to everyone. The vaccine may cause side effects or not work as expected.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRAL INFECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cytomegalovirus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact